Peer power: new study tests if support buddies boost HIV med adherence

NCT ID NCT06501781

Recruiting now Disease control Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether trained peer recovery specialists can help Black individuals with substance use stick to their long-acting injectable HIV treatment or prevention. 186 participants will either get this peer support or standard care. The goal is to see if the peer program improves medication adherence and reduces substance use over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Peer behavioral activation and problem-solving intervention (Peer Activate-LAI)
What this could lead to: If it works, this could provide a scalable, cost-effective way to help Black individuals with substance use stay on HIV treatment or prevention.
What could go wrong: This is a relatively small, early-stage trial (186 people) testing a behavioral intervention, not a drug. Results may not apply to other groups or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease substance abuse substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS SUBSTANCE USE

Contacts and locations

Locations

Baltimore Safe Haven
RECRUITING

Baltimore, Maryland, 21218, United States
HIPS (Harm reduction drop-in center)
RECRUITING

Washington D.C., District of Columbia, 20002, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.